Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates

This article was originally published on Nasdaq

Esperion Therapeutics, Inc. ESPR incurred a loss per share of $1.05 per share for the second quarter of 2022, wider than the Zacks Consensus Estimate of a loss of 95 cents per share. The company reported a loss of $1.67 per share in the year-ago period.